The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma

Cancer Research

Volumn 70, Issue 7, 2010, Pages 2962-2972

  Stumpfova, Magda ^a   Ratner, Desirée ^a   Desciak, Edward B ^a   Eliezri, Yehuda D ^a   Owens, David M ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; STROMAL CELL DERIVED FACTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CELL SURVIVAL; IMMUNOCOMPETENT CELL; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTIGENS, CD; ANTIGENS, SURFACE; CARCINOMA, SQUAMOUS CELL; CELL GROWTH PROCESSES; FEMALE; GENE KNOCKDOWN TECHNIQUES; HUMANS; KERATINOCYTES; MEMBRANE GLYCOPROTEINS; MICE; RECEPTORS, CELL SURFACE; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE;

EID: 77950831816     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-4380     Document Type: Article

References (46)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420: 860-867
2. Chambers AF, Groom AC, MacDonald IC Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2002;2:563-572
3. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006;6: 24-37. (Pubitemid 43053650)
4. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005;5:263-274 (Pubitemid 40488632)
5. French LE, Tschopp J. Defective death receptor signaling as a cause of tumor immune escape. Semin Cancer Biol 2002;12:51-55 (Pubitemid 34087898)
6. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunol Immunother 2004;53:904-910 (Pubitemid 39312657)
7. Toutirais O, Chartier P, Dubois D, et al. Constitutive expression of TGF-β1, interleukin-6 and interleukin-8 by tumor cells as a major component of immune escape in human ovarian carcinoma. Eur Cytokine Netw 2003;14:246-255
8. Somasundaram R, Jacob L, Swoboda R, et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal carcinoma patient is mediated by transforming growth factor-β. Cancer Res 2002;62:5267-5272
9. Shurin MR, Lu L, Kalinski P, Stewart-Akers AM, Lotze MT. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin Immunopathol 1999;21:339-359
10. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-296 (Pubitemid 46697910)
11. Hoek RM, Ruuls SR, Murphy CA, et al. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000;290:1768-1771
12. Wright GJ, Puklavec MJ, Willis AC, et al. Lymphoid/neuronal cell surface OX2 glycoprotein recognizes a novel receptor on macrophages implicated in the control of their function. Immunity 2000;13:233-242
13. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 2004;172:7744-7749
14. Meuth SG, Simon OJ, Grimm A, et al. CNS inflammation and neuronal degeneration is aggravated by impaired CD200-200R-mediated macrophage silencing. J Neuroimmunol 2008;194:62-69
15. Ko YC, Chien HF, Jiang-Shieh YF, et al. Endothelial CD200 is heterogeneously distributed, regulated and involved in immune cellendothelium interactions. J Anat 2009;214:183-195
16. Rosenblum MD, Olasz EB, Yancey KB, et al. Expression of CD200 on epithelial cells of the murine hair follicle: a role in tissue-specific immune tolerance? J Invest Dermatol 2004;123:880-887
17. Copland DA, Calder CJ, Raveney BJ, et al. Monoclonal antibodymediated CD200 receptor signaling suppresses macrophage activation and tissue damage in experimental autoimmune uveoretinitis. Am J Pathol 2007;171:580-588
18. Broderick C, Hoek RM, Forrester JV, Liversidge J, Sedgwick JD, Dick AD. Constitutive retinal CD200 expression regulates resident microglia and activation state of inflammatory cells during experimental autoimmune uveoretinitis. Am J Pathol 2002;161:1669-1677
19. Wright GJ, Cherwinski H, Foster-Cuevas M, et al. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003;171:3034-3046
20. Fallarino F, Asselin-Paturel C, Vacca C, et al. Murine plasmacytoid dendritic cells initiate the immunosuppressive pathway of tryptophan catabolism in response to CD200 receptor engagement. J Immunol 2004;173:3748-3754
21. Boudakov I, Liu J, Fan N, Gulay P, Wong K, Gorczynski RM. Mice lacking CD200R1 show absence of suppression of lipopolysaccharideinduced tumor necrosis factor-α and mixed leukocyte culture responses by CD200. Transplantation 2007;84:251-257
22. Kretz-Rommel A, Qin F, Dakappagari N, et al. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J Immunol 2007;178:5595-5605 (Pubitemid 46674355)
23. Moreaux J, Hose D, Reme T, et al. CD200 is a new prognostic factor in multiple myeloma. Blood 2006;108:4194-4197
24. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia 2007;21:566-568 (Pubitemid 46306574)
25. Petermann KB, Rozenberg Gl, Zedek D, et al. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007;117:3922-3929
26. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol Immunother 2008;57:987-996
27. Owens DM, Romero RM, Gardner C, Watt FM. Suprabasal α6β4 integrin expression in epidermis results in enhanced tumorigenesis and disruption of TGFβ signaling. J Cell Sci 2003;116:3783-3791
28. Jensen UB, Yan X, Triel C, Woo SH, Christensen R, Owens DM. A distinct population of clonogenic and multipotent murine follicular keratinocytes residing in the upper isthmus. J Cell Sci 2008;121: 609-617 (Pubitemid 351524159)
29. Wu WY, Morris RJ. Method for the harvest and assay of in vitro clonogenic keratinocytes stem cells from mice. Methods Mol Biol 2005; 289:79-86.
30. Levy L, Broad S, Zhu AJ, et al. Optimized retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice. Gene Ther 1998; 5:913-922
31. Owens DM, Wei SJ, Smart RC A multihit, multistage model of chemical carcinogenesis. Carcinogenesis 1999;20:1837-1844
32. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001 ; 23:147-159
33. Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Semin Cancer Biol 2004;14:63-69 (Pubitemid 38156128)
34. Quintanilla M, Brown K, Ramsden M, Balmain A. Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986;322:78-80.
35. Bizub D, Wood AW, Skalka AM. Mutagenesis of the Ha-ras oncogene in mouse skin tumors induced by polycyclic aromatic hydrocarbons. Proc Natl Acad Sci U S A 1986;83:6048-6052
36. Rosenblum MD, Woodliff JE, Madsen NA, MeOlash LJ, Keller MR, Truitt RL. Characterization of CD200-receptor expression in the murine epidermis. J Invest Dermatol 2005;125:1130-1138
37. Clark RA, Huang SJ, Murphy GF, et al. Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells. J Exp Med 2008;205: 2221-2234
38. Jaiswal S, Jamieson CH, Pang WW, et al. CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell 2009;138:271-285
39. Ohyama M, Terunuma A, Took CL, et al. Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 2006;116:249-260 (Pubitemid 43121810)
40. Cotsarelis G. Epithelial stem cells: a folliculocentric view. J Invest Dermatol 2006;126:1459-1468
41. Malanchi I, Peinado H, Kassen D, et al. Cutaneous cancer stem cell maintenance is dependent on β-catenin signalling. Nature 2008;452: 650-653
42. Gabrilovich Dl, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-174
43. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8:618-631
44. Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1 +CD11b+ cells in cancer animal models. Int Immunol 2006;18:1-9.
45. Eubank TD, Roberts RD, Khan M, et al. Granulocyte macrophage colony-stimulating factor inhibits breast cancer growth and metastasis by invoking an anti-angiogenic program in tumor-educated macrophages. Cancer Res 2009;69:2133-2140
46. Chen Z, Marsden PA, Gorczynski RM. Role of a distal enhancer in the transcriptional responsiveness of the human CD200 gene to interferon-γ and tumor necrosis factor-α. Mol Immunol 2009;46: 1951-1963